Introduction
Asthma is chronic airway inflammation with variable airflow obstruction (wheeze, breathlessness, cough, chest tightness). Treatment aims at control of symptoms and prevention of exacerbations; the basis is inhaled corticosteroids (ICS), which treat the inflammation.
Key change (GINA since 2019)
No SABA-only treatment for adults and adolescents: relying on salbutamol alone increases the risk of severe attacks and death. Every patient should receive an ICS-containing treatment.
Stepwise treatment (GINA, adults, track 1 preferred)
Track 2: daily ICS (or ICS–LABA such as fluticasone–salmeterol) with SABA as reliever; acceptable when MART is not possible. Leukotriene antagonists (montelukast) are an add-on (neuropsychiatric warnings).
Drugs
Rational prescribing points
- Check inhaler technique and adherence before stepping up; use a spacer with pressurised inhalers.
- Assess control every 1–3 months; step down after 3 months of good control (never stop ICS).
- Written action plan; treat rhinitis, stop smoking, avoid triggers; influenza vaccine.
- Avoid non-selective β-blockers (propranolol, including eye drops) and be cautious with NSAIDs/aspirin in aspirin-sensitive asthma.
Acute exacerbation
Repeated SABA (spacer or nebuliser), oxygen to SpO₂ 93–95%, systemic corticosteroid (prednisolone 40–50 mg for 5–7 days), ipratropium in severe attacks, IV magnesium sulphate for life-threatening attacks; then review the controller.
Every asthmatic needs an inhaled corticosteroid: as-needed or maintenance-and-reliever budesonide–formoterol is now preferred over salbutamol alone.